123TiP: TROPION-Lung14: A phase III study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC)

作者：Sarah B. Goldberg, M. Provencio Pulla, A.E. Lisberg, E. Mascarenhas, Junko Tanizaki, Ying Cheng, H.R. Kim, Yeqiang Liu, Songlin Feng, Lin Zhang, Laurence Toms, Jinneng Yang, Sihai Lu · 发表于：Journal of Thoracic Oncology · 年份：2025 · DOI：10.1016/s1556-0864(25)00318-1 · 被引用次数：5 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Diagnosis and Treatment、Lung Cancer Research Studies